Overview

DYmista NAsal Spray in CHInese Patients

Status:
Completed

Trial end date:
2019-09-24

Target enrollment:

Participant gender:

Summary

This study is a phase III clinical study to assess the efficacy and safety of Dymista® Nasal Spray in comparison to Azep® nasal spray and Flixonase® nasal spray in Chinese patients aged ≥ 12 years with moderate-to-severe allergic rhinitis/rhinoconjunctivitis.

Phase:

Phase 3

Details

Lead Sponsor:

MEDA Pharma GmbH & Co. KG

Treatments:

Azelastine
Fluticasone
Xhance